Navigation Links
MMD in Medical News

Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND

...ry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for mmd may not actually match up with our external assessment, our common stock could be delisted from the Nasdaq Capital Market and other risks and challeng...

Toxic Strand Of RNA Causes Myotonic Muscular dystrophy

...hopes the research might lead to new therapies for mmd in the next few years. "If we develop a therapy to...icroscope. They also integrated an "on switch" for mmd in the mice, activated by giving them doxycycline,...TG repeats, they developed the hallmarks of type 1 mmd within a few weeks, including an inability to rela...
MMD in Medical Technology

Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

... by Year-End - Enrollment On Track in mmd Clinical Study - ALS Expanded Access Pro...ehrig's disease. A Phase 2 trial of IPLEX(TM) in mmd is on-going and a substantial portion of the exter...e Muscular Dystrophy Association in late 2007. mmd Phase 2 trial at-a-glance: -- All sites have been...

Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy

...lopment, and maximize the market opportunities for mmd available to us." Orphan status is granted by th... years of market exclusivity upon approval for the mmd indication. In addition, Insmed is eligible for ta...e drug candidate through the regulatory process. mmd affects approximately 37,000 Americans, and nearly...
MMD in Biological News

American Chemical Society's Weekly PressPac -- Nov. 19, 2008

...most common form of muscular dystrophy in adults. mmd affects about 1 in 8,000 people. Their findings a...udy, Benjamin Miller and colleagues point out that mmd differs from typical hereditary diseases. They re...tivity and cause symptoms of the disease. Rather, mmd is caused by wayward or "toxic" strands of RNA. ...

Toxic molecule may cause most common type of muscular dystrophy

...sulin resistance. Many people don't know they have mmd until their teens or twenties. To prove the...hopes the research might lead to new therapies for mmd in the next few years. "If we develop a therapy to...croscope. They also integrated an "on switch" for mmd in the mice, activated by giving them doxycycline,...
MMD in Biological Technology

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

...tial Initiation of Phase II Trial for IPLEX(TM) in mmd Patients with Severe Insulin Resistance - RIC...s of testosterone. The drug was well tolerated in mmd subjects and demonstrated a safety profile consist...ional Phase II trial focused solely on a subset of mmd patients with severe insulin resistance who, based...

Insmed CEO Resigns Due to Health Concerns

...ry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for mmd may not actually match up with our external assessment, we may lack financial resources to complete development of product candidates and other risks...

Insmed Announces First Quarter 2009 Financial Results

...orward on all fronts. We continue to expect preliminary Phase 2 results in mmd before the end of the second quarter. In addition, the ALS EAP is set to e...e business and develop IPLEX(TM) may be unsuccessful, the actual market for mmd may not actually match up with our external assessment, we may lack financi...

Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule

...ry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for mmd may not actually match up with our external assessment, our common stock could be delisted from the Nasdaq Capital Market and other risks and challeng...

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

...ted an external assessment of the total market for mmd treatments that indicated that the market for mmd could be as high as between $800 million and $1.4 ...tinue moving ahead with our IPLEX(TM) programs for mmd and ALS. In addition, we intend to pursue a compr...

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

...ivity in the current quarter compared to last year as our phase 2 IPLEX(TM) mmd trial continues to progress. SG&A Expenses were consistent quarter over qua....0 million from the Muscular Dystrophy Association supporting the IPLEX(TM) mmd trial. This was partially offset by the absence of license income from Napo...

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants

...d States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency, is currently being investigated in mmd and ALS. About ROP ROP is a disease of the eye that affects prematurely born babies. It is thought to be caused by disorganised growth of retinal ...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

...ategic financial options will ensure that we make informed decisions for moving our FOB program forward, and advancing the development of IPLEX(TM) in mmd and ALS." Revenues for the second quarter ended June 30, 2008 were $2.6 million, up from $2.3 million for the corresponding period in 2007. The incr...

Insmed Announces First Quarter 2008 Financial Results

...llan, President and CEO of Insmed. "We are aggressively pursuing a partner for our FOB program and continue to advance the development of IPLEX(TM) in mmd and ALS." Revenues for the first quarter ended March 31, 2008 were $2.3 million, up from $1.7 million for the corresponding period in 2007. The incr...

Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results

... portion of the external costs associated with the mmd trial; -- Granted Orphan Drug designation for IPLEX(TM) for the treatment of mmd by the FDA, providing the Company with, among othe...sivity upon approval of IPLEX(TM) for the mmd indication; and -- Completed an external ass...
Other Tags
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and ... The American Heart Association hosts their well-known Heart Walk to raise money in awareness ... can be made. Walkers can participate in the cause and someone can also donate, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a ... struggling with chemical dependency, may be able to find some hope in the ... treatment center for addiction located in Western Michigan. Focusing on several different aspects ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Medical Solutions, ... 2015 Best Places to Work in Healthcare by Modern Healthcare and will ... , Now in its eighth year, the Best Places to Work in Healthcare ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ground ... the Food and Drug Administration to eliminate submental fat, also known as the double ... among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , Developed ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... is dedicated to distributing health information technology innovation to transform quality and efficiency ... of the survey will be de-identified and aggregated before being publicly shared to ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
Other Contents